MMR

MORBIDITY AND MORTALITY WEEKLY REPORT

713 Adverse Reactions to Fansidar® and Updated Recommendations for Its Use in the Prevention of Malaria

714 Compendium of Animal Rabies Vaccines, 1985

Current Trends

Adverse Reactions to Fansidar® and Updated Recommendations for its Use in the Prevention of Malaria

Since pyrimethamine-sulfadoxine (Fansidar®) became available in the United States in 1982, it has been an integral part of the malaria prophylaxis regimen that CDC recommends for travelers at risk of exposure to chloroquine-resistant *Plasmodium falciparum* (CRPF). As the areas of the world with transmission of CRPF have expanded, the number of U.S. travelers using Fansidar® has increased. Fansidar® is usually well tolerated; however, as with other sulfonamides, severe adverse reactions associated with its use have been reported (1-5). During the past 3 months, additional cases to those reported in the literature of severe cutaneous reactions (erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis) associated with the use of Fansidar® over the past 2 years have been reported to CDC. These 10 cases (four fatal) that have occurred among U.S. travelers are currently being investigated by CDC in coordination with the U.S. Food and Drug Administration and the drug manufacturer. In addition, there is a collaborative effort under way to assess the risks associated with the use of this drug for malaria prophylaxis.

Until the risk of adverse reactions to Fansidar® is more thoroughly defined, CDC recommends the following:

- 1. Chloroquine remains the primary drug of choice for travelers to all malarious areas (6).
- 2. When considering the use of Fansidar® for chemoprophylaxis of CRPF, physicians should carefully question travelers regarding any previous history of sulfonamide intolerance. Fansidar® should not be prescribed if there is any history of previous untoward reaction to sulfonamides.
- 3. Travelers to CRPF regions in Asia or South America should take Fansidar® in addition to chloroquine only if they stay overnight in rural areas. Travelers visiting urban areas of Asia and South America are at low risk of acquiring malaria, as are travelers to rural areas during daytime hours, because *Anopheles* mosquitoes bite during the evening and night-time hours.
- 4. Travelers to areas of east and central Africa where transmission of CRPF has been documented should continue to use the combination of chloroquine and Fansidar®. The risk of acquiring CRPF in these areas is substantial because of the intense transmission of malaria, especially in those rural areas usually frequented by tourists.
- 5. Travelers should be advised to discontinue Fansidar® use immediately in the event of a possible ill effect, especially if any mucocutaneous signs or symptoms develop, such as pruritus, erythema, rash, orogenital lesions, or pharyngitis.

Fansidar® — Continued

6. Travelers should be informed that, regardless of the prophylactic regimen employed, it is still possible to contract malaria. Medical attention should be sought promptly in the event of a febrile illness, and the physician should be advised of the recent travel history and possibility of exposure to malaria.

The above recommendations differ from earlier statements and should be applied as the most current information available (6-8). CDC will update these interim malaria chemoprophylaxis recommendations in the near future. Additional cases of adverse reactions to Fansidar® should be reported to the Malaria Branch, Division of Parasitic Diseases, Center for Infectious Diseases. CDC. telephone (404) 452-4046.

Reported by Malaria Br, Div of Parasitic Diseases, Center for Infectious Diseases, Div of Quarantine, Center for Prevention Sycs. CDC.

References

- Olsen VV, Loft S, Christensen K. Serious reactions during malaria prophylaxis with pyrimethaminesulfadoxine [Letter]. Lancet 1982;II:994.
- 2. Whitfield D. Presumptive fatality due to pyrimethamine-sulfadoxine [Letter]. Lancet 1982;II:1272.
- Hornstein OP, Ruprecht KW. Fansidar-induced Stevens-Johnson syndrome [Letter]. N Engl J Med 1982;307:1529-30.
- Ligthelm RJ, van Zwienen J, Stuiver PC, Djajadiningrat AP. Syndroom van Stevens-Johnson en granulopenie tijdens het gebruik van sulfadoxine-pyrimethamine (Fansidar). Ned Tijdschr Geneesk 1983:127:1735-7.
- Setia U. Fansidar®-induced Stevens-Johnson syndrome and malaria_prophylaxis [Letter]. Pediatr Infect Dis 1983;2:173-4.
- 6. CDC. Prevention of malaria in travelers 1982. MMWR 1982;31:1S-28S.
- 7. CDC. Imported malaria among travelers—United States. MMWR 1984;33:388-90.
- CDC. Health information for international travel 1984. Atlanta, Georgia: Centers for Disease Control, 1984; HHS publication no. (CDC)84-8280;33:11-58.

Compendium of Animal Rabies Vaccines, 1985 Prepared by: The National Association of State Public Health Veterinarians, Inc.

Part I: Recommendations for Immunization Procedures

The purpose of these recommendations is to provide information on rabies vaccines to practicing veterinarians, public health officials, and others concerned with rabies control. This document will serve as the basis for animal rabies vaccination programs throughout the United States. Its adoption will result in standardization of procedures among jurisdictions, which is necessary for an effective national rabies-control program. These recommendations are reviewed and revised as necessary before the beginning of each calendar year. All animal rabies vaccines licensed by the U.S. Department of Agriculture (USDA) and marketed in the United States are listed in Part II, and Part III describes the principles of rabies control.

A. VACCINE ADMINISTRATION

The Committee recommends that all animal rabies vaccines be restricted to use by or under the supervision of a veterinarian.

B. VACCINE SELECTION

The use of vaccines with 3-year duration of immunity is recommended, since their use constitutes the most effective method of increasing the proportion of immunized dogs and cats in comprehensive rabies-control programs.

C. ROUTE OF INOCULATION

Unless otherwise specified by the product label or package insert, all vaccines must be administered intramuscularly at one site in the thigh.

D. WILDLIFE VACCINATION

Vaccination is not recommended, since no rabies vaccine is licensed for use in wild animals and since there is no evidence that any vaccine will protect wild animals against rabies. The Committee recommends that neither wild nor exotic animals be kept as pets and that wild animals **not** be cross-bred to domestic dogs or cats.

E. ACCIDENTAL HUMAN EXPOSURE TO VACCINE

Accidental human inoculation may occur during administration of animal rabies vaccine. Such exposure to inactivated vaccines constitutes **no known** rabies hazard. No cases of rabies have resulted from needle or other exposure to a licensed, modified live virus vaccine in the United States.

F. IDENTIFICATION OF VACCINATED DOGS

The Committee recommends that all agencies and veterinarians adopt the standard tag system. This will aid the administration of local, state, national, and international procedures. Dog license tags should not conflict in shape and color with rabies tags. It is recommended that anodized aluminum rabies tags not be less than 0.064 inches in thickness.

1. Rabies Tags:

Calendar Year	Color	Shape
1985	Blue	Rosette
1986	Orange	Fireplug
1987	Green	Bell
1988	Red	Heart

Rabies Certificate: All agencies and veterinarians should use form #50 Rabies Vaccination Certificate of the National Association of State Public Health Veterinarians, Inc. (NASPHV), which can be obtained from vaccine manufacturers.

Part II: Vaccines Marketed in the United States and NASPHV Recommendations

Vaccine : generic name	Produced by	Product name Marketed by	For use in*	Dosage †	Age at primary vaccination §	Booster recommended
A. MODIFIED LIVE VIRU	JS					
Canine cell line origin	NORDEN	ENDURALL-R			3 mos. &	
High egg passage	License No. 189	Norden	Dogs	1 ml	1 yr. later	Triennially
			Cats	1 ml	3 mos.	Annually
Canine tissue culture	BOEHRINGER	NEUROGEN-TC			3 mos. &	
origin High cell passage	INGELHEIM License No. 124	Bio-Ceutic	Dogs	1 ml	1 yr. later	Triennially

Vaccine : generic name	Produced by	Product name Marketed by	For use in*	Dosage [†]	Age at primary vaccination §	Booster recommended
B. INACTIVATED						
Murine origin	FORT DODGE License No. 112	TRIMUNE Fort Dodge	Dogs Cats	1 ml 1 ml	3 mos. & 1 yr. later 3 mos. & 1 yr. later	Triennially Triennially
Murine origin	FORT DODGE License No. 112	ANNUMUNE Fort Dodge	Dogs Cats	1 ml 1 ml	3 mos. 3 mos.	Annually Annually
Murine origin	DOUGLAS License No. 165-B	BIORAB-1 Schering Veterinary	Dogs Cats	1 ml 1 ml	3 mos.	Annually
Murine origin	DOUGLAS	BIORAB-3	Dogs	1 ml	3 mos. &	·
	License No. 165-B	Schering Veterinary	Cats	1 ml	1 yr. later 3 mos.	Triennially Annually
Murine origin	WILDLIFE VACCINES, INC.	DURA-RAB 1 Wildlife vaccines	Dogs	1 ml	3 mos.	Annually
	KUNZ-TEBBIT License No. 277	KUNZ-TEBBIT & TechAmerica	Cats	1 ml	3 mos.	Annually
Murine origin	KUNZ-TEBBIT Lincense No. 277	PERFORMER-R Pet Vaccines	Dogs Cats	1 ml 1 ml	3 mos. 3 mos.	Annually Annually
Hamster cell line origin	BEECHAM License No. 225	RABCINE Beecham	Dogs Cats	1 ml 1 ml	3 mos. 3 mos.	Annually Annually
Porcine cell line origin	NORDEN License No. 189	ENDURALL-K Norden	Dogs Cats	1 ml 1 ml	3 mos. 3 mos.	Annually Annually
Porcine cell line origin	NORDEN License No. 189	RABGUARD-TC Norden	Dogs	1 ml	3 mos. & 1 yr. later	Triennially
			Cats	1 ml	3 mos. & 1 yr. later	Triennially
Monkey cell line origin	WELLCOME License No. 107	CYTORAB Wellcome	Dogs Cats	1 ml 1 ml	3 mos. 3 mos.	Annually Annually
Monkey cell line origin	WELLCOME License No. 107	TRIRAB, DELTA- RAB	- Dogs	1 mi	3 mos. & 1 yr. later	Triennially
		Wellcome Fromm	n Cats	1 ml	3 mos.	Annually
Feline cell line origin	FROMM License No. 195-A	RABVAC 1 Fromm	Dogs Cats	1 ml 1 ml	3 mos. 3 mos.	Annually Annually
Feline cell line origin	FROMM License No. 195-A	RABVAC 3 Fromm	Dogs Cats	1 ml	3 mos. & 1 yr. later	Triennially Triennially
Hamster cell line origin	MERIEUX License No. 298	IMRAB Pitman-Moore	Dogs Cats Sheel Cattle Horse	1 ml p 1 ml e 2 ml	3 mos. & 1 yr. later 3 mos. 3 mos.	Triennially Triennially Triennially Annually Annually
Hamster cell line origin	MERIEUX License No. 298	IMRAB-1 Pitman-Moore	Dogs Cats	1 ml 1 ml	3 mos. 3 mos.	Annually Annually

Vaccine : generic name	Produced by	Product name Marketed by	For use in*	Dosage †	Age at primary vaccination §	Booster recommended
C. COMBINATION						
Feline cell line origin	FROMM License No. 195-A	ECLIPSE 3 KP-R Fromm	Cats	1 ml	3 mos.	Annually
Feline cell line origin	FROMM License No. 195-A	ECLIPSE 4 KP-R Fromm	Cats	1 ml	3 mos.	Annually
Monkey cell line origin	WELLCOME License No. 107	CYTORAB RCP Wellcome	Cats	1 ml	3 mos.	Annually
Murine origin	FORT DODGE License No. 112	FEL-O-VAX PCT-R Fort Dodge	Cats	1 ml	3 mos. & 1 yr. later	Triennially

^{*}Refers only to domestic species of this class of animals.

Part III: Principles of Rabies Control

These guidelines have been prepared by the NASPHV for use by government officials, practicing veterinarians, and others who may become involved in certain aspects of rabies control. The NASPHV plans to annually review and revise these recommendations as necessary. Standardized control procedures are needed to deal effectively with the public health aspects of rabies.

A. PRINCIPLES OF RABIES CONTROL

- 1. Humans: Rabies in humans can be prevented by eliminating exposure to rabid animals and by promptly treating local wounds and immunizing when exposed. Current recommendations of the Immunization Practices Advisory Committee (ACIP) for preexposure and postexposure prophylaxis are suggested for consideration by attending physicians. These recommendations, along with the current status of animal rabies in the region and information concerning the availability of rabies biologics, are available from state health departments.
- 2. Domestic Animals: Local governments should initiate and maintain effective programs to remove stray and unwanted animals and ensure vaccination of all dogs and cats. Since cat rabies cases now exceed those annually reported in dogs, immunization of cats should be required. Such procedures in the United States have reduced laboratory-confirmed rabies cases in dogs from 8,000 in 1947 to 132 in 1983. The recommended vaccination procedures and the licensed animal vaccines are specified in Parts I and II of the NASPHV's annually released Compendium.
- 3. Wildlife: The control of rabies in foxes, skunks, raccoons, and other terrestrial animals is very difficult. Selective reduction of these populations, when indicated, may be useful, but the utility of this procedure depends heavily on the circumstances surrounding each rabies outbreak. (See C: Control Methods in Wild Animals.)

[†]All vaccines must be administered intramuscularly at one site in the thigh unless otherwise specified by the label.

[§]Three months is the earliest age recommended; dogs and cats vaccinated between 3 and 12 months should be revaccinated 1 year later.

B. CONTROL METHODS IN DOMESTIC AND CONFINED ANIMALS

- Preexposure Vaccination and Management: Animal rabies vaccines, because of species limitations, techniques, and tolerances, should be administered only by or under the direct supervision of a veterinarian. Within 1 month after vaccination, a peak rabies antibody titer is reached, and the animal can be considered immunized. (See Parts I and II for recommended vaccines and procedures.)
 - a. **Dogs and Cats**: All dogs and cats should be vaccinated against rabies commencing at 3 months of age and revaccinted in accordance with Part II of this Compendium.
 - b. **Livestock**: It is not economically feasible, nor is it justified from a public health standpoint, to vaccinate all livestock against rabies. Veterinary clinicians and owners of valuable animals may consider immunizing certain breeding stock located in areas where wildlife rabies is epizootic.

c. Other Animals:

- (1) Animals Maintained in Exhibits and Zoological Parks: Captive animals not completely excluded from all contact with local vectors of rabies can become infected with rabies. Moreover, such animals may be incubating rabies when captured. Exhibit animals, especially carnivores and omnivores having contact with the viewing public, should be quarantined for a minimum of 180 days. Since no rabies vaccine is licensed for use in wild animals, vaccination, even with inactivated vaccine, is not recommended. Preexposure rabies immunization of animal workers at such facilities is recommended to protect the workers and to reduce the need for euthanizing a valuable animal for rabies testing after it has bitten a handler.
- (2) Wild Animals: Because of the existing risk of rabies among wild animals, such as raccoons, skunks, and foxes, the American Veterinary Medical Association (AVMA), the NASPHV, and the Conference of State and Territorial Epidemiologists strongly recommend the enactment of state laws prohibiting the interstate and intrastate importation, distribution, and relocation of wild animals and wild animals cross-bred to domestic dogs and cats. Further, these same organizations continue to recommend the enactment of laws prohibiting the distribution or keeping of wild animals as pets.
- 2. Stray-Animal Control: Stray dogs and cats should be removed from the community, especially in rabies-epizootic areas. Local health department and animal-control officials can enforce the pick-up of strays more efficiently if owned animals are confined or leashed when not confined. Strays should be impounded for at least 3 days to give owners sufficient time to reclaim animals apprehended as strays and to determine whether human exposure has occurred.

3. Quarantine:

a. International: Present USDA regulations (CFR No. 71154) governing the importation of wild and domestic felines, canines, and other potential rabies vectors are minimal for preventing the introduction of rabid animals into the United States. All dogs and cats imported from countries with endemic rabies should be vaccinated against rabies at least 30 days before entry into the United States.* CDC is responsible for these animals imported into the United States. CDC's requirements should be

^{*}In regard to cats, these recommendations do not conform to the official recommendations of CDC and the U.S. Public Health Service. Although domestic feline rabies has increased, there has been no evidence of increased risk of imported rabies in cats. U.S. Foreign Quarantine Regulations do not require rabies vaccinations for imported cats.

coordinated with interstate shipment requirements. The health authority of the state of destination should be notified within 72 hours of any animal conditionally admitted into its jurisdiction.

The conditional admission of such animals into the United States must be subject to state and local laws governing rabies. Failures to comply with these requirements should be promptly reported to the director of CDC.

- b. Interstate: Before interstate shipment, dogs and cats should be vaccinated against rabies according to the Compendium's recommendations, preferably at least 30 days before shipment. While in shipment, they should be accompanied by a currently valid NASPHV Form #50 Rabies Vaccination Certificate. One copy of the certificate should be mailed to the appropriate Public Health Veterinarian or State Veterinarian of the state of destination.
- c. Health Certificates: If a certificate is required for dogs and cats in transit, it must not replace the NASPHV rabies vaccination certificate.
- 4. Adjunct Procedures: Methods or procedures that enhance rabies control include:
 - a. Licensure: Registration of licensure of all dogs and cats may be used as a means of rabies control by controlling the stray-animal population. Frequently, a fee is charged for such licensure, and revenues collected are used to maintain a rabies- or animal-control program. Vaccination is usually recommended as a prerequisite to licensure.
 - b. Canvassing of Area: This includes house-to-house calls by members of the animal-control program to enforce vaccination and licensure requirements.
 - c. Citations: These are legal summonses issued to owners for violations, including the failure to vaccinate or license their animals.
 - d. Leash Laws: All communities should adopt leash laws that can be incorporated in their animal-control ordinances.
- 5. Postexposure Management: ANY DOMESTIC ANIMAL THAT IS BITTEN OR SCRATCHED BY A BAT OR BY A WILD, CARNIVOROUS MAMMAL THAT IS NOT AVAILABLE FOR TESTING SHOULD BE REGARDED AS HAVING BEEN EXPOSED TO A RABID ANIMAL.
 - a. Dogs and Cats: When bitten by a rabid animal, unvaccinated dogs and cats should be destroyed immediately. If the owner is unwilling to have this done, the unvaccinated animal should be placed in strict isolation for 6 months and vaccinated 1 month before being released. Dogs and cats that are currently vaccinated should be revaccinated immediately and observed by the owner for 90 days.
 - b. Livestock: All species of livestock are susceptible to rabies infection; cattle appear to be among the most susceptible of all domestic animal species. Livestock known to have been bitten by rabid animals should be destroyed (slaughtered) immediately. If the owner is unwilling to have this done, the animal should be kept under very close observation for 6 months.

The following are recommendations to owners of livestock exposed to rabid animals:

(1) If slaughtered within 7 days of being bitten, tissues may be eaten without risk of infection, providing liberal portions of the exposed area are discarded. Federal meat inspectors will reject for slaughter any animal that has been exposed to rabies within 8 months.

(2) No tissues or secretions from a clinically rabid animal should be used for human or animal consumption. However, because pasteurization temperatures will inactivate rabies virus, drinking pasteurized milk or eating completely cooked meat does not constitute a rabies exposure.

C. CONTROL METHODS IN WILD ANIMALS

Bats and wild carnivorous mammals, as well as wild animals cross-bred to domestic dogs and cats, that bite people should be killed, and appropriate tissues should be sent to the laboratory for examination for rabies. A person bitten by a bat or any wild animal should immediately report the incident to a physician who can evaluate the need for antirabies treatment. (See current ACIP rabies prophylaxis recommendations: Rabies Prevention—United States, 1984. MMWR 1984;33:393-402, 407-8.)

 Terrestrial Mammals: Since there is no evidence that these costly programs reduce either wildlife reservoirs or rabies incidence on a statewide basis, persistent, continuous, and routine trapping or poisoning campaigns as a means of wildlife rabies control

(Continued on page 725)

TABLE I. Summary—cases of specified notifiable diseases, United States

		51st Week En	ding	Cumulat	ive, 51st Week	Ending
Disease	Dec. 22, 1984	Dec. 24, 1983	Median 1979-1983	Dec. 22, 1984	Dec 24, 1983	Median 1979-1983
Acquired Immunodeficiency Syndrome (AIDS)	188	63	N	4.386	2.075	N
Aseptic meningitis	77	132	121	7.943	12.299	9,358
Encephalitis: Primary (arthropod-borne	,,	132	121	7,943	12,233	0,000
& unspec.)	31	18	20	1.164	1,796	1.500
Post-infectious	31	4	20	82	95	95
Gonorrhea: Civilian	15.649	14,741	15,859	822.089	883,944	978,492
Military	388	380	380	19.999	23.534	26,230
Hepatitis: Type A	385	393	453	21.070	20.915	25.034
Type B	512	524	419	25,592	23,654	20,466
Non A, Non B	72	63	419 N	3.664	3,355	N
Unspecified	82	151	179	5.324	7,102	10,345
Legionellosis	17	13	N	645	7,102	N N
Leprosy	8	3	3	234	236	230
Malaria	0	5	9	955	774	1.019
Measles: Total**	9 5	8	21	2.531	1,450	2,957
Indigenous	5	9	N N	2,331	1 146	2,00. N
Imported	5	,	Ň	2,239	305	N.
Meningococcal infections: Total	44	41	60	2.609	2,641	2.660
Civilian	44	41	60	2,609	2,625	2.641
Military	44	41	60	2,604	16	16
Mumps	48	58	140	2.857	3.295	5.208
Pertussis	18	58	44	2,164	2.328	1,636
Rubella (German measles)	13	9	37	742	947	2.281
Syphilis (Primary & Secondary): Civilian	456	579	489	26.974	31,579	30,435
Military	450	7	3	20,974	31,575	360
Toxic Shock syndrome	11	5	Ň	457	362 421	N
Tuberculosis	445	432	503	21,197	23.095	26,660
Tularemia	3	432	503 4	21,197	23,095	255
	. 7	5	8	365	451	495
Typhoid fever						1,100
Typhus fever, tick-borne (RMSF)	2 30	5 69	5	848	1,100	6,058
Rabies, animal	30	69	69	5,124	5,788	0,050

TABLE II. Notifiable diseases of low frequency, United States

	Cum. 1984		Cum. 1984
Anthrax	1	Plague	31
Botulism: Foodborne (Calif. 1)	20	Poliomyelitis: Total	4
Infant (Calif. 2)	92	Paralytic	4
Other	6	Psittacosis (N.C. 1, Tex. 1)	89
Brucellosis (Fla. 1)	120	Rabies, human	3
Cholera	1 1	Tetanus	64
Congenital rubella syndrome	4	Trichinosis	61
Diphtheria	1	Typhus fever, flea-borne (endemic, murine) (Tex. 1)	37
Leptospirosis (Mass. 1)	31		

The 1983 reports which appear in this table were collected before AIDS became a notifiable condition.

^{**}There were no cases of internationally imported measles reported for this week.

721

TABLE III. Cases of specified notifiable diseases, United States, weeks ending

December 22, 1984 and December 24, 1983 (51st Week)

		Aseptic	Encep	halitis	Gono	rrhea	Н	epatitis (V	'iral), by ty	ре	Lagional	
Reporting Area	AIDS	Menin- gitis	Primary	Post-in- fectious		ilian)	Α	В	NA,NB	Unspeci- fied	Legionel- losis	Leprosy
	Cum. 1984	1984	Cum. 1984	Cum. 1984	Cum. 1984	Cum. 1983	1984	1984	1984	1984	1984	Cum. 1984
UNITED STATES	4,386	77	1,164	82	822,089	883,944	385	512	72	82	17	234
NEW ENGLAND Maine	151	5	49	3	22,876 999	23,311	8 1	33	5	9	-	11
N.H. ✓t.	3	-	7	-	709	1,102 720	-	2		-	-	-
Mass.	1 87	-	5 22	-	373 9,818	434 10,136	5	3 19	1 3	8	-	6
R.I. Conn.	6 54	2 3	15	3	1,586 9,391	1,256 9,663	2	3 4	1 -	1	-	4 1
MID ATLANTIC	1,919	5	125	9 .	109,611	114,908	40	115	5	12	-	37
Jpstate N.Y. N.Y. City	167 1,400	4	41 11	7	17,799 42,280	18,745 46,132	6 28	21 85	2	4 7	-	3 32
N.J. Pa	263 89	1 U	28 45	2	19,896 29,636	21,360 28,671	6 U	9 U	3 U	1 U	Ū	2
E.N. CENTRAL	189	13	336	18	118,562	125,846	26	51	6	8	8	7
Ohio Ind.	20 26	2 4	108 84	9	31,216 12,280	32,262 12,694	9 2	10 8	2 1	1 2	1 5	3
II. Mich	102 31	3 4	40 67	6	27,970 34,238	36,077 33,380	1 14	2 31	3	1 4	2	2
Wis	10	-	37	3	12,858	11,433	-	-	-	-	-	-
W.N. CENTRAL Minn.	41 11	1	103 50	3	40,971 6,152	41,480 5,781	-	3	-	-	-	4 2
lowa Mo	2	1	32	=	4,490	4,498	-	-	-	-	-	1
N. Dak.	23	-	11	-	19,641 388	20,399 435	-	2	-	-	-	1
S. Dak. Nebr	3	-	2 1	1	983 3.028	1,036 2,693	-	-	-	-	-	-
Kans.	2	-	7	2	6,289	6,638	-	1	-	-	-	-
S. ATLANTIC Del.	582 5	20	174 1	17	200,113 3,977	230,115 4,205	26 5	111	20 1	9	6	14
Md D.C	52 90	-	33	-	23,764 14,932	29,466 15,645	1	9 16	2	-	1	1
/a.	37	3	31	5	19,974	20,853	-	8	1	1	3	4
W. Va. N.C.	5 14	1 5	40 33	7	2,642 33,945	2,574 35,403	2	12	4	3	1	-
S.C. Ga.	8 57	1	5 2	2	21,328 28,722	21,015 48,587	2 5	15 18	2	2 1	1	1
Fla.	314	9	29	3	50,829	52,367	11	32	8	2	-	7
E.S. CENTRAL Ky.	26 11	4	55 13	8	74,549 8,818	73,848 8,744	20 11	19 4	1	-	-	-
Ténn. Ala.	6	2	19 20	1 6	29,980 22,732	30,355 22,625	2	10		-	-	-
Miss.	3	i	3	1	13,019	12,124	1	1	-	-	-	-
N.S. CENTRAL Ark	303	8	109	4 2	110,301 9,986	123,292 9,752	61 3	35 2	5	19 2	2	25 1
.a.	56	3	12		24,331	23,686	2	2	-	2	-	i
Okla. Tex.	10 236	1 4	19 78	1	12,347 63,637	14,146 75,708	20 36	2 29	2 3	3 12	2	23
MOUNTAIN Mont	75	. 6	37	11	27,252 1,034	27,996	40	33	8	5	-	8
daho	-	-	-	-	1,259	1,204 1,255	8	1		-	-	-
Wyo. Colo.	1 36	1	14	-	728 7,840	737 7,789	1 5	7	1	3	-	-
N. Mex. Ariz	3 21	4	12	3	3,235 7,714	3,446 7,952	1 19	1 12	1 5	1	-	6
Jtah Nev	7	1	10	8	1,288 4,154	1,346 4,267	2	10	1	i	-	1
PACIFIC	1,100	15	176	9	117,854	123,148	164	112	22	20	1	128
Wash. Oreg.	54 14		9	-	8,656 6,534	9,763 6,546	17	4	2	1	1	14
Calif.	1,018	14	163	9	97,872	101,441	140	98	18	19	-	2 92
Alaska Hawaii	12	1	4	-	2,874 1,918	3,112 2,286	1 -	1 -	-	-	-	20
Guam P.R.		U		-	103	130	U	Ų	U	U	U	_
V.I.	71 -	2 U	3	2	3,263 427	2,615 320	Ū	2 U	Ū	4 U	Ü	5
Pac. Trust Terr.	-	U	-	-	-	-	Ū	Ū	ŭ	ŭ	ŭ	-

TABLE III. (Cont'd.) Cases of specified notifiable diseases, United States, weeks ending December 22, 1984 and December 24, 1983 (51st Week)

	December 22, 1984 and December 24, 1983 (51st Week)														
	Malaria	India	Mea:	sles (Rub	eola)	Total	Menin- gococcal Infections	Mui	mps		Pertussis			Rubella	
Reporting Area	Cum. 1984	1984	Cum. 1984	1984	Cum. 1984	Cum. 1983	Cum. 1984	1984	Cum. 1984	1984	Cum. 1984	Cum. 1983	1984	Cum. 1984	Cum. 1983
UNITED STATES	955	5	2,239	-	292	1,450	2,609	48	2,857	18	2,164	2,328	13	742	947
NEW ENGLAND Maine	48	-	94	-	12	21	175 1	4	100 30	1	71 4	73 5	1	23 1	19
N.H. Vt.	7	-	33	-	3 5	3	11 31	-	21 5	-	14 23	10 8	-	1	5 5
Mass.	26	-	49	-	-	9	70	2	23	-	21	38	1	20	7
R.I. Conn.	4 11	-	10	-	4	9	18 44	1	11 10	1	4 5	5 7	-	1	2
MID ATLANTIC Upstate N.Y.	143 28	-	135 42	-	44 14	119 18	445 140	-	330 99	1	196 109	392 118	1	232 99	147 32
N.Y. City N.J.	48 37	-	89 4	-	20	71	90	-	35	-	16	56	1	106 23	86 3
Pa.	30	Ü	-	Ū	3 7	27 3	88 127	Ū	138 58	Ū	13 58	20 198	Ū	4	26
E.N. CENTRAL Ohio Ind.	84 20	-	619 3	-	75 6	718 88	419 138	26 11	1,108 516	6 1	469 80	512 155	1 -	99 2	139
III.	4 28	-	2 181	-	1	406 216	54 89	2 10	78 202	5	246 26	60 179	1	5 62	27 61
Mich. Wis.	17 15	-	411 22	-	54 13	7	86 52	3	197 115	-	31 86	42 76	-	22 8	20 29
W.N. CENTRAL Minn.	25 8	-	49 44	-	9	. 8	163 35	4 2	112	1	128	201 49	-	39 4	44 9
lowa Mo.	2	-	-	-	-	-	23	1	26	1	16 15	9	-	1	-
N. Dak.	8 1	-	5	-	1	1	53 2	-	10	-	20	23 3	-	3	- :
S. Dak. Nebr.	1	-	-	-	-	-	6		2	-	9	8	-	-	-
Kans.	3 2	-	-	-	5	6	13 31	1	4 61	-	13 55	4 105	-	31	35
S. ATLANTIC Del.	133 4	-	19	-	33	206	540 4	3	207 3	1	238	268 5	1	30 2	102
Md. D.C.	31	-	8	-	14	11	40	1	43	-	2 78	34	-	ĩ	3
Va.	1 36	-	1	-	5 4	23	8 68	-	19	-	15	50	-	1	2
W. Va. N.C.	1 15	-	-	-	-	-	6	1	42	-	11	9	-	-	10
S.C.	2	-	-	-	1	1	88 57	1	23 5	-	37 1	31 14	-	-	10
Ga. Fla.	15 28	-	1 9	-	1 8	8 159	104 165	-	22 50	1	18 76	70 55	1	2 24	16 70
E.S. CENTRAL	11	-	1	-	5	27	144	_	55	1	15	33		20	19
Ky. Tenn.	2 2	-	1	-	2	1	51	-	11	-	2	. 14	-	14	18
Ala. Miss.	7	-	-	-	3	5	41 35	-	17 6	1	7 2	8 5	-	3	1
W.S. CENTRAL	86	5	601	-	-	21	17	-	21	-	4	6	-	3	123
Ark.	-	-	8	-	25	79 13	296 53	3	186 8	- 1	329 19	462 27	1	69 3	-
La. Okla.	9 10	-	8	-		29	58	-	-	-	10	12	-	-	10
Тех.	67	5	585	-	8 17	1 36	29 156	N 3	N 178	-	241 59	335 88	1	66	113
MOUNTAIN Mont	29 2		113	-	32	41	87	3	266	2	124	235	-	22	37 3
daho	2		-	-	23	4 10	2 10	-	11 10	-	19 7	2 16	-	1	8
Nyo. Colo.	-	-	-	-	-	1	3	-	2	-	6	6	-	3	9
N. Mex.	8 1	-	88	-	6	3	31 8	1 N	29 N	2	47	137 13	-	2 1	-
Ariz. Utah	11	-	-	-	1	1	18	2	196	-	12 24	29	-	4	8 7
Nev.	5 -	-	25	-	2	22	9 6	-	11 7	-	7 2	31 1	-	7 4	í
PACIFIC Wash.	396 20	-	608	-	57	231	340	5	493	5	594	152	8	208	317 9
Oreg.	14		157	-	15	35 10	53 49	- N	53	3	324	20 10	-	2 2	14
Calif. Naska	357	-	292	-	38	182	229	N 5	N 402	2	30 163	115	8	197	292 1
lawaii	5	-	159	-	4	2 2	8 1	-	14 24	-	1 76	4	-	1 6	i
Guam P.R.	1	U	83	U	2	4	1	U	5	U			U	2	8
/ .l.	-	Ū	235	Ū	-	96 5	8	U	173		1	14	- U	20	2
Pac. Trust Terr.	-	U	-	ŭ	-	-	-	U	5	U	-	-	Ü	-	-

For measles only, imported cases includes both out-of-state and international importations.

N Not notifiable

U: Unavailable

TABLE III. (Cont'd.) Cases of specified notifiable diseases, United States, weeks ending December 22, 1984 and December 24, 1983 (51st Week)

-		(Civilian)	Toxic-			Tula	Typhoid	Typhus Fever	Rabies,
Reporting Area	(Primary &	Secondary)	shock Syndrome		culosis	Tula- remia	Fever	(Tick-borne) (RMSF)	Animal
	Cum. 1984	Cum. 1983	1984	Cum. 1984	Cum. 1983	Cum. 1984	Cum. 1984	Cum. 1984	Cum. 1984
UNITED STATES	26,974	31,579	11	21,197	23,095	287	365	848	5,124
NEW ENGLAND Maine	524 10	671 19	1	660 36	709 36	7	23	6	48 13
N.H.	14	22	-	27	36	-	-	-	16
Vt. Mass.	1 287	3 435	1	8 359	11 386	7	18	4	11
R.I.	22	23	-	55	62	-	-	-	-
Conn.	190	169	-	175	178	-	5	2	8
MID ATLANTIC	3,663	4,219	-	3,827	4,122	3	57	27	537
Upstate N.Y. N.Y. City	281 2,228	404 2,434	-	601 1,576	639 1.667	2	12 19	10 3	126
N.J.	662	811	-	829	842	. ī	18	3	37
Pa.	492	570	U	821	974	-	8	11	374
E.N. CENTRAL Ohio	1,379	1,684	2 1	2,783	3,145	10	59	53	211
Ind.	239 143	446 151	i	515 356	511 375	2	7 12	28 7	27 21
III.	568	757	-	1,136	1,330	8	23	15	74
Mich. Wis.	354 75	236 94	-	623 153	772 157	-	8 9	3	21 68
W.N. CENTRAL	352	382	1	642	732	83	12	53	747
Minn.	89	147	i	117	155	1	5	1	94
lowa	11 184	23 144	-	67 314	65 364	45	-	6	149
Mo. N. Dak.	9	2	-	13	8	45	5	18	67 140
S. Dak.	1	11	-	24	38	34	-	5	203
Nebr. Kans.	15 43	15 40	-	30 77	25 77	3	2	5 18	44 50
S. ATLANTIC	7,729	8,563	1	4,476	4.607	8	42	395	1,511
Del.	21	43	-	56	67	-	-	1	6
Md. D.C.	474 336	506 377	-	434 182	369 191	1 1	2 6	28	846
Va.	402	550	-	459	499	i	8	48	209
W. Va. N.C.	20 845	26 870		131 713	132 735	1	1	7 178	40 25
S.C.	770	569	-	542	438		i	80	59
Ga. Fla.	1,059 3,802	1,525 4,097	1	662 1,297	764 1,412	4	9 15	48 5	186 140
	2,009	2,122	_	2,011	2,049	7		94	
E.S. CENTRAL Ky.	99	172	-	500	498	í	10 2	94 19	259 53
Tenn.	539	578	-	597	635	5	2	49	79
Ala. Miss.	667 704	815 557	-	564 350	517 399	1	2 4	15 11	127
W.S. CENTRAL	6,538	8,047		2,426	2,828	120	25	201	992
Ark.	191 1.170	187 1,626	-	283 337	348 436	84 7	2	28 4	101
La. Okla.	209	1,626	-	232	436 276	21	4	119	60 102
Tex	4,968	6,040	-	1,574	1,768	8	19	50	729
MOUNTAIN	654 4	651	4	586	646	36	13	13	280
Mont. Idaho	23	7 8	1	28 28	42 32	3 8	1	8 1	124 11
Wyo.	4	12	-	5	14	1	-	3	27
Colo. N. Mex.	184 91	149 177	1	78 109	98 114	8 3	5 3	1	39 12
Ariz.	236	168	1	262	259	4	3	-	45
Utah Nev.	18 94	23 107	1	35 41	41 46	4 5	1	-	6 16
PACIFIC	4,126	5,240	2	3,786	4,257	13	124	6	
Wash.	138	194	1	189	231	3	3	6 2	539 3
Oreg.	117 3,788	143	1	145	179	2	2	1	1
Calif. Alaska	3,788	4,810 14	-	3,163 75	3,540 73	8	110 1	2 1	527 8
Hawaii	77	79	-	214	234	-	8	-	-
Guam	-	-	U	5	9	-	=	-	-
P.R. V.I.	770 11	879 19	Ū	406 3	455 2		5 3	-	62
Pac. Trust Terr.	-	-	ŭ	-	-	-	-	-	-

TABLE IV. Deaths in 121 U.S. cities,* week ending December 22, 1984 (51st Week Ending)

	December 22, 1984 (51st Week Ending)														
		All Caus	es, By A	ge (Year	s)		P&I**			All Cause	s, By A	ge (Years	3)		P&I**
Reporting Area	All Ages	≥65	45-64	25-44	1-24	<1	Total	Reporting Area	All Ages	≥65	45-64	25-44	1-24	<1	Total
Albany, N.Y. Allentown, Pa. Buffalo, N.Y. Camden, N.J. Elizabeth, N.J.	685 164 38 36 28 46 32 24 8 32 24 8 49 38 44 60 2,703 60 11 103 38 39	489 103 25 29 23 28 27 18 26 6 6 29 37 45 1.817 38 65 26 29	138 35 11 7 5 12 3 5 6 14 18 3 6 7 6 7 6 7 5 3 9 8	10 2	13 8 - - 1 1 - 1 - 2 72 5 - 3 1 1	19 8 2 2 1 3 3 - 1 4 4 39 2 - 2	56 18 2 5 7 3 1 1 1 5 4 139 3 6 13	S. ATLANTIC Atlanta, Ga Baltimore, Md Charlotte, N. C. Jacksonville, Fla. Miami, Fla. Norfolk, Va Richmond, Va. Savannah, Ga. St. Petersburg, Fla Tampa, Fla. Washington, D.C. Wilmington, Del. E.S. CENTRAL Birmingham, Ala. Chattanoaga, Tenr Knoxville, Tenn. Louisville, Kya. Memphis, Tenn. Mobile, Ala Montgomery, Ala	72 275 69 798 131	867 88 114 60 61 73 48 60 29 100 48 145 41 483 74 31 36 85 132 23 31	321 36 39 29 28 29 14 22 5 5 66 18 31 16 20 34 45 6	117 144 131 112 66 33 33 55 34 7 65 12 35 8 15 64	30 3 2 1 1 1 3 3 5 1 1 9 -	57 8 7 3 4 3 2 - 1 1 2 3 3 3 3 1 0 - - - - - - - - - - - - - - - - - -	57 4 5 5 5 5 2 6 4 3 10 7 5 1 5 1 7 5 1 8 4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Erie, Pa † Jersey City, N.J. N.Y. City, N.Y. Newark, N.J. Paterson, N.J. Philadelphia, Pa.† Pittsburgh, Pa.† Reading, Pa. Rochester, N.Y. Schenectady, N.Y. Scranton, Pa.† Syracuse, N.Y. Trenton, N.J. Utica, N.Y. Yonkers, N.Y.	48 54 1,526 48 30 301 75 32 113 25 29 82 28 24 37	40 38 991 25 19 200 55 28 87 19 22 59 20 30	4 8	2 5	2 3 3 9 4 9 1 3 1	24 2 1 1 1 1 - 1 2 - 2	3 2 1 72 3 6 9 2 1 1	Nashville, Tenn. W.S. CENTRAL Austin, Tex Baton Rouge, La Corpus Christi, Tey Dallas, Tex. El Paso, Tex. Fort Worth, Tex Houston, Tex Little Rock, Ark New Orleans, La San Antonio, Tex Shreveport, La Tulsa, Okla	130 1,234 55 51	71 782 38 35 43 109 35 73 105 61 85 120 25 53	38 278 7 11 13 49 14 25 51 15 35 40 4	12 99 5 3 8 16 3 9 20 5 10 14 3 3	4 36 4 1 4 4 9 1 2 3 1 3	39 1 1 3 10 4 1 2 4 2 5 4 2	56 5 1 4 4 10 7 5 3 9 2 6
Akron, Ohio Canton, Ohio Chicago, III § Cincinnati, Onio Cleveland, Ohio Columbus, Ohio Dayton, Ohio Detroit, Mich. Evansville, Ind. Fort Wayne, Ind. Gary, Ind. Grand Rapids, Micl Indianapolis, Ind. Madison, Wis.	187 39	1,696 58 24 415 145 98 80 84 161 34 31 111 43 111 25	10 8 5 59 51 32 68 17 13 5 46 6	3 1 7 8 12 8 5 26 4 1 2 1 14 4	65 3 11 2 7 2 1 9 2 1 1 2 8 3	87 3 1 12 7 5 8 3 15 1 3	87 -2 11 20 4 2 2 9 3 2 1 3 4	MOUNTAIN Albuquerque, N M Colo Springs, Colo Denver, Colo. Las Vegas, Nev Ogden, Utah Phoenix, Ariz. Pueblo, Colo. Salt Lake City, Uta Tucson, Ariz. PACIFIC Berkeley, Calif. Fresno, Calif. Glendale, Calif.	117 83 13 140 27	436 46 27 80 52 10 93 21 29 78 1.569 10 42 36	143 23 8 23 20 1 24 5 8 31 454 2	46 3 5 6 2 13 1 9 7	25 3 4 5 3 5 4 1 62 2	17 1 4 2 4 2 4 2 4 2	28 4 9 6 - - 1 8 118 2 4 3
Milwaukee, Wis- Peoria, III. South Bend, Ind. Toledo, Ohio Youngstown, Ohio W.N. CENTRAL Des Moines, Iowa Duluth, Minn. Kansas City, Kans. Kansas City, Mo Lincoln, Nebr. Minneapolis, Minn. Omaha, Nebr. St. Louis, Mo. St. Paul, Minn. Wichita, Kans.	145 49 38 48 154 81 763 68 39 129 103 88 170 85 24	110 37 29 35 109 56 531 50 29 30 84 17 67 67 116 53 18	26 6 5 8 39 15 145 13 7 5 32 1 24 12 32 14 5	4 2 1 4 38 3 7 - 4 3 12 9	1 2 2 3 3 2 16 1 1 2 2 1 3 2 1	4 4 2 2 4 33 1 1 2 4 - 5 6 7 7	4 5 1 3 7 3 3 7 3 3 7 1 8 1 1 5 3 3 7 4	Honolulu, Hawaii Long Beach, Calif. Los Angeles, Calif. Pasadena, Calif. Portland, Oreg. Sacramento, Calif. San Diego, Calif. San Diego, Calif. San Francisco, Cal San Jose, Calif. Seattle, Wash. Spokane, Wash. Tacoma, Wash.	67 98 848 89 36 156 135	37 71 592 56 27 117 94 97 103 99 96 28 64	19 15 143 15 4 23 25 28 54 38 27 14 25 2,706	5 5 76 9 3 6 10 9 22 8 8 1 4	1 4 24 3 3 5 1 6 7 2	5 3 8 6 2 7 3 3 3 - 3 2 2 2	7 4 24 3 7 11 14 7 15 2 3 8 625

^{*} Mortality data in this table are voluntarily reported from 121 cities in the United States, most of which have populations of 100,000 or more A death is reported by the place of its occurrence and by the week that the death certificate was filed Fetal deaths are not

^{**} Pneumonia and influenza

Fineumorita and influence

1 Because of changes in reporting methods in these 4 Pennsylvania cities, these numbers are partial counts for the current week Complete counts will be available in 4 to 6 weeks.

11 Total includes unknown ages.

[§] Data not available. Figures are estimates based on average of past 4 weeks.

should be abolished. However, limited control in high-contact areas (picnic grounds, camps, suburban areas) may be indicated for the removal of selected, high-risk species of wild animals. The public should be warned not to handle wild animals. The state game department should be consulted early to manage any elimination programs when requested to do so by the state health department.

2 Bats:

- a. Rabid bats have been reported from every state except Hawaii and have caused human rabies infections in the United States. It is neither feasible nor practical, however, to control rabies in bats by areawide bat-population reduction programs.
- b. Bats should be eliminated from houses and surrounding structures to prevent direct association with people. Such structures should then be made bat-proof by sealing routes of entrance with screen or other means.

THE NASPHV COMPENDIUM COMMITTEE: Melvin K. Abelseth, DVM, PhD, Chairman; John I. Freeman, DVM, MPH; Russell J. Martin, DVM, MPH; Grayson B. Miller, Jr., MD; James M. Shuler, DVM, MPH; R. Keith Sikes. DVM. MPH.

CONSULTANTS TO THE COMMITTEE: William H. H. Clark, DVM, AVMA Council on Public Health & Regulatory Veterinary Medicine; Kenneth L. Crawford, DVM, MPH; David A. Espeseth, DVM, Veterinary Biologics Staff, APHIS, USDA; Howard Koonse, Representative, Veterinary Biological Section, Animal Health Institute; Robert H. Miller, PhD, Representative, Veterinary Biological Section, Animal Health Institute; William G. Winkler, DVM, MS, CDC, PHS, HHS.

ENDORSED BY: Conference of State and Territorial Epidemiologists; AVMA Council on Public Health and Regulatory Veterinary Medicine.

Erratum: Vol. 33, No. 49

p. 687. In the article, "Acute Convulsions Associated with Endrin Poisoning—Pakistan," the chemical name for DDT in the sixth line of the third paragraph should be: 1,1,1-tri-chloro-2,2-dis(4-chlorophenyl)ethane.

TABLE I. Summary—cases of specified notifiable diseases, United States

		2nd Week En	ding	Cumulat	ive, 52nd Week	1983 1979-1983 2.075 N			
Disease	Dec. 29, 1984	Dec. 31, 1983	Median 1979-1983	Dec. 29, 1984	Dec. 31, 1983				
Acquired Immunodeficiency Syndrome (AIDS)*	102		N	4.488	2 075				
Aseptic meninaitis	94	227	164	8.036	12.526	9,521			
Encephalitis: Primary (arthropod-borne	34	221	104	0,000					
& unspec.)	17	51	40	1.179	1,847	1,540			
Post-infectious	'í	6	3	83	101	101			
Gonorrhea: Civilian	11.087	14.160	14.160	833.454	898,104	992,446			
Military	229	257	404	20.228	23,791	26,477			
Hepatitis: Type A	434	561	727	21,512	21,476	25,761			
Туре В	496	828	652	26,102	24,482	21,118			
Non A. Non B	66	94	Ň	3.731	3,449	N			
Unspecified	76	149	243	5.405	7,251	10,666			
Legionellosis	8	74	Ň	651	821	N			
Leprosy	4	15	8	238	251	238			
Malaria	18	31	31	973	805	1,041			
Measles: Total**	Ž	47	48	2.534	1,497	3,012			
Indigenous		5	N	2.239	1,151	N			
Imported	2	42	Ň	295	347	N			
Meningococcal infections: Total	31	88	86	2.641	2,729	2,729			
Civilian	31	88	85	2.636	2,713	2,713			
Military		-		5	16	16			
Mumps	64	53	102	2.921	3,348	5,310			
Pertussis	19	132	74	2.187	2,460	1,660			
Rubella (German measles)	1 3	12	27	745	959	2,308			
Syphilis (Primary & Secondary): Civilian	289	556	459	27.258	32,135	30,876			
Military	6	8	5	283	390	361			
Toxic Shock syndrome	3	31	Ň	461	452	N			
Tuberculosis	468	745	745	21,701	23,840	27,396			
Tularemia	4	11	11	292	304	271			
Typhoid fever	3	46	10	368	497	499			
Typhus fever, tick-borne (RMSF)		13	11	847	1,113	1,113			
Rabies, animal	43	36	85	5,175	5,824	6,171			

TABLE II. Notifiable diseases of low frequency, United States

	Cum. 1984		Cum. 1984
Anthrax	1	Plaque	31
Botulism: Foodborne	20	Poliomyelitis: Total	4
Infant (Calif. 1)	93	Paralytic	4
Other	6	Psittacosis (Conn. 3, Va. 73)	165
Brucellosis (Mo. 1, Okla. 1)	122	Rabies, human	3
Cholera	1 1	Tetanus	64
Congenital rubella syndrome	4	Trichinosis (N.C. 1)	62
Diphtheria	1	Typhus fever, flea-borne (endemic, murine)	37
Leptospirosis (Hawaii 1)	32		

^{*}The 1983 reports which appear in this table were collected before AIDS became a notifiable condition.

[&]quot;The two reported cases for this week were imported from a foreign country or can be directly traceable to a known internationally imported case within two generations.

TABLE III. Cases of specified notifiable diseases, United States, weeks ending December 29, 1984 and December 31, 1983 (52nd Week)

	Γ	Aseptic	Encephalitis		G	orrhea	Н	lepatitis (V	iral), by ty	pe	Legionel-	Γ	
Reporting Area	AIDS	Menin- gitis	Primary	Post-in- fectious		vilian)	Α	В	NA,NB	Unspeci- fied	losis	Leprosy	
	Cum. 1984	1984	Cum. 1984	Cum. 1984	Cum. 1984	Cum. 1983	1984	1984	1984	1984	1984	Cum. 1984	
UNITED STATES	4,488	94	1,179	83	833,454	898,104	434	496	66	76	8	238	
NEW ENGLAND Maine	153	4	49	3	23,461 1,031	23,726 1,119	4	30	1	9	1	11	
N.H. Vt.	3		7	-	721	727 441	1	4	-	-	-	-	
Mass. R.I.	1 87	2	5 22	-	380 10,023	10,256	2	14	-	9	1	6	
Conn.	6 56	2	15	3	1,607 9,699	1,273 9,910	1	8 3	1 -	-	-	4 1	
MID ATLANTIC	1,970	14	127	9	111,907	117,312	25	66	4	4	-	37	
Upstate N.Y. N.Y. City	168 1,441	6	42 11	7	18,118 44,152	19,354 46,854	9 16	11 47	-	3	-	3 32	
N.J. Pa.	270 91	8 U	29 45	2	20,001 29,636	21,859 29,245	Ū	8 U	4 U	Î U	U	2	
E.N. CENTRAL	198	9	337	18	119,258	128,013	15	31	4	1	-	7	
Ohio Ind	29	1	108	9	31,340	33,374	9	7	1	1	-	3	
III.	26 102	U	84 40	6	12,280 28,022	12,763 36,243	U 1	U 5	U 1	U	U -	2	
Mich. Wis.	31 10	8	68 37	3	34,758 12,858	34,106 11,527	5	19	2	-	-	2	
W.N. CENTRAL	44	6	103	3	41,294	42,168	23	21	4	-	1	4	
Minn. Iowa	12 2	2 2	50 32	-	6,202 4,574	5,811 4,620	16 1	12 3	2 1	-	-	2 1	
Mo.	25	-	11	-	19,808	20,750	-	5	i	-	-	i	
N Dak. S. Dak.	-	-	2	1	394 1,001	437 1,037	6	-	-	-	-	-	
Nebr. Kans.	3 2	2	1	2	3,026 6,289	2,766 6,747	-	1	-	-	1	-	
S. ATLANTIC		-	7 180	18	201,605	234.051	23	- 85	8	6	3	14	
Del	589 5	25 1	1	-	4,046	4,274	-	1	-	-	-	-	
Md. D.C.	52 92	5	33	:	23,909 15,062	30,038 15,891	1	28 4	1	1	-	1	
Va.	40	-	31	5	20,171	21,119	-	i	1	1	2	4	
W. Va. N.C.	5 14	9	40 34	8	2,731 34,308	2,610 35,785	1 1	5	-	1	1	-	
S.C. Ga.	9 57	2	5 2	2	21,422 28,722	21,231 49,733	3	12 11	-	-	-	1	
Fla	315	8	34	3	51,234	53,370	17	23	6	3	-	7	
E.S. CENTRAL	26	9 3	55	8	75,632 8,997	74,706 8,851	1	19 7	1	5 4	-	-	
Ky. Tenn.	11 6	-	13 19	1	30,603	30,840	-	9	1	1	-	-	
Ala. Miss.	6 3	6	20 3	6 1	22,957 13,075	22,625 12,390	-	2 1	-	-	-	-	
W.S. CENTRAL	307	8	110	4	110,764	124,685	62	30	4	17	2	25	
Ark. La.	1 56	1	12	2	9,986 24,590	9,752 23,686	-	1	-	-	-	1	
Okla. Tex.	10 240	2 5	19 79	1 1	12,551 63,637	14,284 76,963	13 49	3 26	1 3	17	2	23	
MOUNTAIN	75	3	37	11	27,734	28,476	51	24	5	11		8	
Mont.	-	-	-		1,046	1,221	-	-	-	-	-	-	
ldaho Wyo.	1	-	-	-	1,275 743	1,287 740	13	2	-	-	-	-	
Colo.	36	1	14	-	7,987	7,961	9	9 1	1	5	-	-	
N. Mex. Ariz.	3 21	2	12	3	3,302 7,851	3,514 8,047	17	6	2 1	6	-	6	
Utah Nev.	7 7	-	10 1	8	1,310 4,220	1,362 4,344	1 7	3 3	1	-	-	1 1	
PACIFIC	1,126	16	181	9	121,799	124,967	230	190	35	23	1	132	
Wash. Oreg.	59 14	2	10	:	8,862 6,648	9,995 6,643	19 32	11 13	2 5	2 1	1	14	
Calif.	1,039	14	167	9	101,405	102,861	179	163	28	20	-	96	
Alaska Hawaii	2 12	-	4	-	2,934 1,950	3,167 2,301	-	1 2	-	-	-	20	
Guam	-	U	-		103	164	Ų	Ų	U	υ	U	-	
P.R. V.I.	74	Ū	5	2	3,319 427	2,854 326	1 U	3 U	- U	1 U	Ū	5	
Pac. Trust Terr.	-	ŭ	-	-	-		ŭ	ŭ	ŭ	ŭ	ŭ	-	

TABLE III. (Cont'd.) Cases of specified notifiable diseases, United States, weeks ending December 29, 1984 and December 31, 1983 (52nd Week)

 									(52na week)							
Reporting Area	Malaria	Indig	Mea: enous	sles (Rubeola) Imported * Total		Total	Menin- gococcal Infections	Mumps		l	Pertussis	5	Rubella			
	Cum. 1984	1984	Cum. 1984	1984	Cum. 1984	Cum. 1983	Cum. 1984	1984	Cum. 1984	1984	Cum. 1984	Cum. 1983	1984	Cum. 1984	Cum. 1983	
UNITED STATES	973	-	2,239	2	295	1,497	2,641	64	2,921	19	2,187	2,460	3	745	959	
NEW ENGLAND Maine	48	-	94	-	12	21	181	-	100	2	73	75	-	23	21	
N.H.	-	-	33	-	3	3	11	-	30 21	-	4 14	5 10	-	1	5	
Vt. Mass.	7 26	-	2 49	-	5	9	33 71	- :	5 23	2	25 21	8 40	-	20	5 8	
R.I. Conn.	4 11	-	10	-	4	9	19 46	-	11	-	4 5	5 7	-	1	3	
MID ATLANTIC Upstate N.Y.	144	-	135	-	44	120	447	14	344	4	200	452	2	234	148	
N.Y. City	28 48	-	42 89	-	14 20	18 72	141 90	4 10	103 45	1	110 19	119 61	2	99 108	32 87	
N.J. Pa.	38 30	Ū	4	Ū	3 7	27 3	89 127	Ū	138 58	Ū	13 58	20 252	Ū	23	3 26	
E.N. CENTRAL	84	-	619		75	756	423	18	1,126		469	524		99	142	
Ohio Ind.	20 4	Ū	3 2	Ū	6 1	88 406	141 54	2	518	-	80	158	-	2	2	
III.	28	-	181	-	1	216	89	U 9	78 211	U	246 26	63 179	U	5 62	27 63	
Mich. Wis.	17 15	-	411 22	-	54 13	45 1	87 52	7	204 115	-	31 86	46 78	-	22 8	21 29	
W.N. CENTRAL Minn.	26	-	49	-	9	8	164	1	113		128	227	-	39	45	
lowa	8 2	-	44	-	3	1	36 23	-	9 26	-	16 15	49 9	-	4 1	9	
Mo. N. Dak.	8 1	-	5	-	1	1	53	1	11	-	20	23	-	-	-	
S. Dak.	i	-	- :	-	-	-	2 6	-	2	-	9	3 8	-	3	-	
Nebr. Kans.	4 2	-	-	-	- 5	- 6	13 31	-	4 61	-	13 55	130	-	31	36	
S. ATLANTIC Del.	136	-	19	-	34	206	546	3	210	3	245	278	_	30	102	
Md.	4 32	-	8	-	14	11	4 40	1	3 44	-	2 78	5 39	-	2 1	3	
D.C. Va.	1 36	-	1	-	5	-	8		-		-	-	:	-	-	
W. Va.	1	-		-	4	23	68 6	-	19 42	-	19 11	50 9	-	1	2	
N.C. S.C.	15 2		-	-	1	1	88	-	23	-	37	34	-	-	10	
Ga. Fla.	15 30	-	1 9	-	1 9	8 159	58 106	-	5 22	-	1 18	14 70	-	2	1 16 70	
E.S. CENTRAL	12	_	1		5	27	168	2	52	3	79	57	-	24		
Ky.	2	-	1	-	-	1	150 53	-	55 11	-	15 2	33 14	-	20 14	19 18	
Tenn. Ala.	2 8	-	-	-	2	- 5	44 36	-	17	-	7	8	-	-	1	
Miss.	-	-	-	-	-	21	17	-	6 21	-	2 4	5 6	-	3 3		
N.S. CENTRAL Ark.	86	-	601 8	-	25	79 13	297 53	4	190	-	329	477	1	70	126	
.a.	9	-	8	-	-	29	58	-	8		19 10	28 12	-	3	10	
Okla. Tex.	10 67	-	585	-	8 17	1 36	29 157	N 4	N 182	-	241 59	347 90	1	67	116	
MOUNTAIN Mont	31	-	113	-	32	41	87	9	275	3	127	240		22	38	
daho	2 2	-	-	-	23	4 10	2 10	-	11	-	19	2	-	-	4 8	
Nyo. Colo.	-	-	-	-	-	1	3	-	10 2		7 6	16 6	-	1 3	9	
N. Mex.	10 1		88	-	6	3	31 8	2	31	-	47	138	-	2	1	
Ariz. Jtah	11	-	-	-	1	1	18	N 7	N 203	3	12 27	13 33	-	1 4	8	
Nev.	5	-	25 -	-	2	22	9 6	-	11	-	7 2	31	-	7 4	7 1	
PACIFIC Vash.	406	-	608	2	59	239	346	15	508	7	601	154	_	208	318	
reg.	20 15	-	157	-	15	43 10	56 49	2 N	55	-	324	20	-	2 2	9 14	
Calif. Naska	366	-	292	-	38	182	232	13	N 415	1	30 164	10 117	-	197	293	
lawaii	5	-	159	2†	6	2 2	8 1	-	14 24	6	1 82	4	-	1 6	1	
iuam .R.	1 4	U	83	U	2	4	1	U	5	U			U	2	-	
/.l.	-	Ū	256	Ū	-	96 5	7	u U	173 5	Ū	1	14	Ū	20	8 2	
ac. Trust Terr.	-	U	-	Ū	-	-	-	Ü	5	U	-	-	U	-	-	

For measles only, imported cases includes both out-of-state and international importations.

TABLE III. (Cont'd.) Cases of specified notifiable diseases, United States, weeks ending December 29, 1984 and December 31, 1983 (52nd Week)

		ecember		nu Dece	iliber 31,	1983 (52)	iu vveek)		
Reporting Area	Syphilis (Primary &	(Civilian) Secondary)	Toxic- shock Syndrome	Tube	rculosis	Tula- remia	Typhoid Fever	Typhus Fever (Tick-borne) (RMSF)	Rabiès, Animal
	Cum. 1984	Cum. 1983	1984	Cum. 1984	Cum 1983	Cum. 1984	Cum. 1984	Cum. 1984	Cum. 1984
UNITED STATES	27,258	32,135	3	21,701	23,840	292	368	847	5,175
NEW ENGLAND Maine	529 10	686 19	-	679 36	749 37	7	23	6	48
N.H.	14	22	-	27	38	_			13 16
Vt.	1	4	-	8	11		. 5	-	-
Mass. R.I.	292 22	443 23	-	376 56	391 66	7	18	4	11
Conn.	190	175	-	176	206	-	5	2	8
MID ATLANTIC	3,713	4,282	-	3,937	4,202	3	57	27	539
Upstate N.Y. N.Y. City	290 2,256	419 2,461	-	612 1,656	658 1,701	2	12 19	10 3	128
N.J.	675	825	-	848	859	1	18	3	37
Pa.	492	577	U	821	984	-	8	11	374
E.N. CENTRAL Ohio	1,397 239	1,684 446	-	2,804 528	3,230 519	11 2	60 7	52 · 27	211 27
Ind.	143	151	Ū	356	382	-	12	7	21
III.	580	757	-	1,136	1,380	8	23	15	74
Mich. Wis.	360 75	236 94	-	631 153	785 164	1 -	9 9	3	21 68
W.N. CENTRAL	355	385	2	657	786	83	13	53	763
Minn.	91	149 23	1 -	117	165	1	5	1	107
lowa Mo.	11 185	145	-	68 32 7	65 399	45	5	6 18	150 67
N. Dak.	9	2	-	13	9	-	-	-	140
S. Dak. Nebr.	1 15	11 15	1	25 30	46 25	34	1	5 5	203 46
Kans.	43	40	-	77	77	3	2	18	50
S. ATLANTIC	7,842	8,728	-	4,572	4,789	9	42	395	1,526
Del. Md.	21 480	43 517	-	56 441	67 372	2	2	1 28	6 846
D.C.	339	379	-	188	199	1	6	-	-
Va.	415 20	567 26	-	459 132	520 135	1	8	48	209
W. Va. N.C.	855	887	-	753	780	1	1	7 178	40 25
S.C.	774	580	-	541	443	-	1	80	59
Ga. Fla.	1,059 3,879	1,550 4,179	-	705 1,297	816 1,457	4 -	9 15	48 5	194 147
E.S. CENTRAL	2,018	2,156	-	2,036	2,096	7	10	94	263
Ky. Tenn.	99 547	176 587	-	510 606	525 645	1 5	2 2	19 49	53 81
Ala.	668	815	-	565	523	-	2	15	129
Miss.	704	578	-	355	403	1	4	11	-
W.S. CENTRAL Ark.	6,553 191	8,189 187	1	2,511 291	2,915 368	122 84	25	201 28	994 101
La.	1,183	1,650	-	379	446	7	2	4	60
Okla. Tex.	211 4,968	196 6,156	1	239 1,602	276 1,825	23 8	4 19	119 50	104 729
MOUNTAIN	671	666		618	681	36	13	13	285
Mont.	4	7	-	33	42	3	1	8	126
ldaho	23	10	-	28	35	8	-	1	11
Wyo Colo.	4 193	12 150	-	5 92	14 109	1 8	5	3 1	28 39
N. Mex.	97	183	-	112	116	3	3	-	12
Ariz.	237 19	174 23	-	266 39	266 47	4 4	3	-	47
Utah Nev.	94	107	-	43	52	5	1	-	6 16
PACIFIC	4,180	5,359	-	3,887	4,392	14	125	6	546
Wash. Oreg.	138 117	196 146	-	199 155	240 182	4 2	4 2	2 1	3 1
Calif.	3,840	4,923	-	3,244	3,636	8	110	2	534
Alaska	6 79	15 79	-	75 214	98	-	1	1	8
Hawaii	79	79	-		236	-	8	-	-
Guam P.R.	796	928	U -	5 421	15 455	-	5	-	62
V.I.	11	19	U U	3	2	-	3	-	-
Pac. Trust Terr.	-	-	U	-	-	-	-	-	-

TABLE IV. Deaths in 121 U.S. cities,* week ending December 29, 1984 (52nd Week Ending)

		All Caus	es, By A	ge (Year:	s)				All Causes, By Age (Years)						
Reporting Area	All Ages	≥65	45-64	25-44	1-24	<1	P&I** Total	Reporting Area	All Ages	≥65	45-64	25-44	1-24	<1	P&I** Total
NEW ENGLAND	730	513	152	33	16	15	55	S. ATLANTIC	950	592	221	76 4	33	27 4	33
Boston, Mass. Bridgeport, Conn.	196	127	48 9	8	9	4	24	Atlanta, Ga. Baltimore, Md.	95 232	56 144	26 58	17	5 8	5	2
Cambridge, Mass.	48 17	37 11	5	1	1	1	2 5	Charlotte, N.C.	64	33	18	7	4	2	5
Fall River, Mass.	32	24	7	1	-	_	1	Jacksonville, Fla.	56	35	11	5	2	3	5
Hartford, Conn.	77	53	17	5	-	1	1	Miami, Fla.	116	69	34	11	1	1	-
Lowell, Mass.	26	22	3	-	1	-	1	Norfolk, Va.	35 32	23 20	5 7	2 3	2	3 1	5 2
Lynn, Mass. New Bedford, Mass	18 26	15 21	3 4	1	-	-	2 1	Richmond, Va. Savannah, Ga.	35	21	5	8	i		2
New Haven, Conn.	67	45	12	5	1	4	1	St. Petersburg, Fla.	81	66	10	3		2	5
Providence, R.I.	71	54	13	2	ż	-	4	Tampa, Fla.	58	36	10	5	5	1	2
Somerville, Mass.	9	8	1	-	-	-	-	Washington, D.C.	85	47	25	9	2	2	2
Springfield, Mass.	40	25	12	1	2	-		Wilmington, Del.	61	42	12	2	2	3	-
Waterbury, Conn. Worcester, Mass.	32 71	24 47	4 14	4 5	-	5	2 11	E.S. CENTRAL	688	446	140	37	30	35	51
WOICESTEI, WISS.	<i>,</i> ,	47	14	5	-	5	''	Birmingham, Ala.	87	61	15	3	1	7	ĭ
MID. ATLANTIC	2,384	1,633	493	159	46	53	98	Chattanooga, Tenn		35	8	6	1	-	7
Albany, N.Y.	49	39	4	3	-	3	1	Knoxville, Tenn.	59	45	6	4	4	-	4
Allentown, Pa.	12	9	3	-	-	-	-	Louisville, Ky. Memphis, Tenn.	103 216	71 113	23 50	1 18	. 5 1 5	3 20	5 23
Buffalo, N.Y. Camden, N.J.	104	69 18	21 7	6 4	2 1	6	4	Mobile, Ala.	82	54	21	3	15 3	1	23 5
Elizabeth, N.J.	28	22	5	-	1		1	Montgomery, Ala.	22	16	3	-	1	2	1
Erie, Pa.†	34	22	9	1		2	i	Nashville, Tenn.	69	51	14	2	-	2	5
Jersey City, N.J.	50	34	8	3	-	5	1								
N.Y. City, N.Y.	1,441	962	298	117	35	29	57	W.S. CENTRAL	989	648	189	59	36	47	31
Newark, N.J. Paterson, N.J.	53 26	29 16	13	7 .	3	1	3	Austin, Tex. Baton Rouge, La.	32 32	19 18	9 5	1 4	1	2	1 2
Philadelphia, Pa.†	158	103	44	6	2	3	4	Corpus Christi, Tex		13	3	3	-	1	-
Pittsburgh, Pa.t	46	34	11	ĭ	-	-	-	Dallas, Tex.	160	86	46	13	6	9	4
Reading, Pa.	32	29	3	-	-	-	3	El Paso, Tex.	38	20	10	4	2	2	2
Rochester, N.Y.	107	89	15	2	1	-	8	Fort Worth, Tex.	75	39	20	6	2	8	3
Schenectady, N.Y. Scranton, Pa.†	32 23	26 17	5 5	1	-		1	Houston, Tex.§ Little Rock, Ark.	252 69	216 44	3 20	5 1	11 3	8 1	4
Syracuse, N.Y.	92	65	18	5	1	1	1	New Orleans, La.	102	56	27	12	2	4	-
Trenton, N.J.	25	19	5	ĭ		-	i	San Antonio, Tex.	107	68	27	4	3	5	8
Utica, N.Y. Yonkers, N.Y.	26 16	20 11	6 4	ī	-	-	2	Shreveport, La. Tulsa, Okla.	31 71	20 49	7 12	2 4	1 2	1 4	5
E.N. CENTRAL					-			MOUNTAIN	639	409			_		47
Akron, Ohio	1,952 41	1,493 31	258 7	82 2	48 1	56	80	Albuquerque, N.Me		409	131 17	50 5	26 2	23 4	13
Canton, Ohio	26	16	8	-	i	1		Colo Springs, Colo		28	6	2	4	1	9
Chicago, III §	458	414	5	7	11	12	11	Denver, Colo.	118	75	29	6	5	3	10
Cincinnati, Onio	91	60	20	5	4	2	12	Las Vegas, Nev	81	44	20	12	3	2	-
Cleveland, Ohio	140	88	35	9	4	4	3	Ogden, Utah	20	17	2	. 1	-	:	3
Columbus, Ohio Dayton, Ohio	119 97	78 62	21 24	9 6	2 1	9	3	Phoenix, Ariz. Pueblo, Colo.	167 18	106 15	36 2	11	10	4	3
Detroit, Mich. §	293	257	3	8	8	11	6 7	Salt Lake City, Utah		34	8	4	-	4	1
Evansville, Ind.	29	28	ĭ	-	-	٠.	í	Tucson, Ariz.	76	50	11	8	2	5	8
Fort Wayne, Ind.	50	35	5	8	2	-	i i								
Gary, Ind.	12	7	4	-	-	1		PACIFIC Calif	1,822	1,378	271	81	46	35	92
Grand Rapids, Micl Indianapolis, Ind.	h. 57 107	43 68	8 26	5 4	1 5	4	5 2	Berkeley, Calif. Fresno, Calif.	17 97	10 60	4 30	2 3	2	1 2	3 11
Madison, Wis.	37	24	26 5	2	1	5	3	Glendale, Calif. §	29	29	30	3	-	- 2	1
Milwaukee, Wis.	94	69	22	1	i	1	3	Honolulu, Hawaii	62	36	16	6	4	-	4
Peoria, III.	43	28	10	3	1	i	7	Long Beach, Calif.	98	67	21	4	2	4	2
Rockford, III.	42	32	4	4	2	-	1	Los Angeles, Calif.	514	475	5	1	16	6	14
South Bend, Ind.	33	23	9	1	-	-	2	Oakland, Calif.	61 26	44 20	9	3	5		3
Toledo, Ohio Youngstown, Ohio	117 66	83 47	26 15	4 4	3	1	8 5	Pasadena, Calif. Portland, Oreg.	26 91	69	15	1 2	3	1 2	1 9
oungstown, Onto	30	47	15	4	-	-	5	Sacramento, Calif.	127	86	29	7	1	4	9
W.N. CENTRAL	592	405	112	33	21	21	30	San Diego, Calif.	135	82	32	16	2	3	10
Des Moines, Iowa	41	28	7	2	3	1	3	San Francisco, Calif		78	19	13	4	5	5
Duluth, Minn.	7	5	1	1	-	-	-	San Jose, Calif.	175	128	33	9	-	5	12
Kansas City, Kans.	29	20	5	1	2	1	[Seattle, Wash	126 24	89 19	27 5	8	2	-	3
Kansas City, Mo.	110 16	71 11	24 3	8 1	4	3	7	Spokane, Wash. Tacoma, Wash.	121	86	22	6	5	2	5
Lincoln, Nebr. Minneapolis, Minn.	71	49	9	5	5	3	2	. Journa, Wasii.				U	5		3
Omaha, Nebr.	68	49	17	ĭ	-	1	4	TOTAL	10,746 [†]	[†] 7,517	1,967	610	302	312	517
St. Louis, Mo.	125	93	17	7	6	2	11								
St. Paul, Minn.	54 71	37 42	12 17	2 5	1	3 6	2								
Wichita, Kans.															

^{*} Mortality data in this table are voluntarily reported from 121 cities in the United States, most of which have populations of 100,000 or more. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included.

^{**} Pneumonia and influenza

Because of changes in reporting methods in these 4 Pennsylvania cities, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks.

 Total includes unknown ages.

[§] Data not available. Figures are estimates based on average of past 4 weeks.

The Morbidity and Mortality Weekly Report is prepared by the Centers for Disease Control, Atlanta, Georgia, and available on a paid subscription basis from the Superintendent of Documents, U.S. Government Printing Office, Washington, D.C. 20402, (202) 783-3238.

The data in this report are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the succeeding Friday.

The editor welcomes accounts of interesting cases, outbreaks, environmental hazards, or other public health problems of current interest to health officials. Such reports and any other matters pertaining to editorial or other textual considerations should be addressed to: ATTN: Editor, Morbidity and Mortality Weekly Report, Centers for Disease Control, Atlanta, Georgia 30333.

Director, Centers for Disease Control James O. Mason, M.D., Dr.P.H. Director, Epidemiology Program Office Carl W. Tyler, Jr., M.D.

Editor Michael B. Gregg, M.D. Assistant Editor Karen L. Foster, M.A.

DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Centers for Disease Control Atlanta GA 30333

Official Business
Penalty for Private Use \$300



Postage and Fees Paid U.S. Dept. of H.H.S. HHS 396

S *HCRH NEWV75 8129 DR VERNE F NEWHOUSE VIROLOGY DIVISION CID 7-B14 X